Sterile preparation evolves: A USP <797> implementation story

Hospital Pharmacy

Volumn 41, Issue 1, 2006, Pages 49-58

  Stein, Susan M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Aseptic training; Beyond use dating; Risk level; Sterile preparation; USP <797>

Indexed keywords

ALPHA 1 ANTITRYPSIN; FLUOROURACIL; INSULIN; POTASSIUM CHLORIDE; VANCOMYCIN;

ARTICLE; CONTAMINATION; DRUG FORMULATION; INSTRUMENT STERILIZATION; PERSONNEL; PHARMACY; PRACTICE GUIDELINE; PROFESSIONAL PRACTICE; QUALITY CONTROL; STANDARDIZATION; TRAINING;

EID: 31544458149     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1310/hpj4101-49     Document Type: Article

References (22)

1. Hughes CF, Grant AF, Leckie BD, Baird DK. Cardioplegic solution: a contamination crisis. J Thorac Cardiovasc Surg. 1986;91:296-302.
2. Associated Press. Pittsburgh woman loses eye to tainted drugs; 12 hurt. Baltimore Sun. November 9, 1990:3A.
3. Dugleux G, Coutour X, Hecquard C, Oblin I. Septicemia caused by contaminated parenteral nutrition pouches: the refrigerator as an unusual cause. JPEN J Parenter Enteral Nutr. 1991;15:474-475.
4. Solomon SL, Khabbaz RF, Parker RH, et al. An outbreak of Candida parapsilosis bloodstream infections in patients receiving parenteral nutrition. J Infect Dis. 1984;149:98-102.
5. Pierce LR, Gaines A, Varricchio R, Epstein J. Hemolysis and renal failure associated with use of sterile water for injection to dilute 25% human albumin solution. Am J Health Syst Pharm. 1998;55:1057, 1062, 1070.
6. Lumpkin MM. Safety Alert: Hazards of precipitation with parenteral nutrition. Am J Hosp Pharm. 1994;51:1427-428.
7. American Society of Health-System Pharmacists. ASHP technical assistance bulletin on quality assurance for pharmacy prepared sterile products. Am J Hosp Pharm. 1993;50:2386-2398.
8. th rev: <1206> Sterile Drug Products for Home Use. Presented at: The United States Pharmacopeial Convention; 1994; Rockville, MD.
9. Model rules for sterile pharmaceuticals. Nat Assoc Board Pharm. 1993:12.1-3.
10. Santell JP, Kamalich RF. National survey of quality assurance activities for pharmacy prepared sterile products in hospitals and home infusion facilities-1995. Am J Health Syst Pharm. 1996;53(21):2591-2605.
11. Morris AM, Schneider PJ, Pederson CA, Mirtallo JM. National survey of quality assurance activities for pharmacy-compounded sterile preparations. Am J Health Syst Pharm. 2003;60(24):2567-2576.
12. nd ed. Chapter <797> Pharmaceutical Compounding - Sterile Preparations. Presented at: The United States Pharmacopeial Convention; 2003; Rockville, MD.
13. US Pharmacopeial Convention, Inc. General Notices. United States Pharmacopeia 27/National Formulary 22. Presented at: US Pharmacopeial Convention; April 2004; Rockville, MD.
14. Joint Commission to survey compliance with new USP-NF chapter on compounding sterile preparations. JT Comm Perspect. 2004;24(4):4-5.
15. Fricker M, Trissel L, Rich D. Turning a new chapter on IV drug compounding safety: USP/NF chapter <797>. Hosp Pharm. 2004;39(9):899-920.
16. Newton, DW. Proposed revisions to USP chapter <797> pharmaceutical compounding - sterile preparations. Drug standards. Available at: http://64.233. 187.104/search?q=cache:OT_hlMshGb8 J:www.usp.org/healthcareInfo/pharmInfo/ revisions797.html+Newton,+DW.+Pr oposed+Revisions+to+USP+Chapter+%3C797%3E+& hl=en.Accessed on February 7, 2005.
17. Food and Drug Administration. Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing. Cur Good Man Pract. 2004:1-59.
18. National Institute for Occupational Safety and Health. Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. Department of Health and Human Services, Center for Disease Control and Prevention; Washington, DC: September 2004.
19. Controlled Environment Testing Association. Frequently asked questions relating to controlled environment facility and equipment requirements of USP <797>. Available at: http://www.cetainternational.org/reference/usp797faq. pdf. - Accessed on February 7, 2005.
20. Tillett L. Barrier isolators as an alternative to a clean room. Am J Health Syst Pharm. 1999;56(14):1433-1436.
21. Rahe H. Understanding the critical components of a successful clean room and barrier isolator project. Am J Health Syst Pharm. 2000;57(4):346-350.
22. DeChant RL, Furtado D, Smith FM, et al. Determining a time frame for sterility testing of intravenous admixtures. Am J Hosp Pharm. 1982;39:1305-1308.